Liquidia Corp (NASDAQ:LQDA)
| Market Cap | $4.90B+87.0% |
| Revenue (ttm) | $621.87M+798.4% |
| Net Income | -$94.19M+22.7% |
| EPS | -$1.23+14.0% |
| Shares Out | 90.11M |
| PE Ratio | n/a |
| Forward PE | 14.03 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,690,880 |
| Open | $56.19 |
| Previous Close | $56.63 |
| Day's Range | $54.09 - $57.21 |
| 52-Week Range | $22.31 - $93.61 |
| Beta | 0.54 |
| Analysts | Buy |
| Price Target | $78.18(+43.63%) |
| Earnings Date | Mar 4, 2027 |
About LQDA
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
7 firms rating LQDA in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 4, 2027Earnings report
$LQDA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in LQDA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by LQDA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
LQDA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
LQDA Revenue by Segment
| Litigation settlement, net | $389.75M | 59.96% |
| Segment Information | $222.74M | 34.27% |
| Personnel, including stock-based compensation | $37.57M | 5.78% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New LQDA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to LQDA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in LQDA
| IJRiShares Core S&P Small-Cap ETF | $253.39M |
| IWMiShares Russell 2000 ETF | $104.33M |
| VTIVanguard Morningstar Total Stock Market ETF | $80.76M |
| XSMOInvesco S&P SmallCap Momentum ETF | $50.01M |
| SPSMState Street SPDR Portfolio S&P 600 Small Cap ETF | $38.44M |
| VXFVanguard Extended Market ETF | $37.99M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from LQDA’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 earnings beat with strong YUTREPIA sales growth of 31% and positive post-settlement outlook drive bullish coverage, though some mixed messaging on revenue growth and losses remains.
Recent Insider Activity
Insider Score Trend Over Time
-38.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| TYNE | Direxion Nanotechnology ETF | 6.10% |
| CAFG | Pacer US Small Cap Cash Cows Growth Leaders ETF | 2.93% |
| PJP | Invesco Pharmaceuticals ETF | 2.36% |
| PSCH | Invesco S&P SmallCap Health Care ETF | 2.16% |
| XSMO | Invesco S&P SmallCap Momentum ETF | 1.89% |
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 1.67% |
| NTRL | First Trust Merger Arbitrage ETF | 1.40% |
| RZG | Invesco S&P SmallCap 600 Revenue ETF | 1.16% |
| BBP | Virtus Biotech ETF | 1.00% |
| JSMD | Janus Henderson Small/Mid Cap Growth Alpha ETF | 0.89% |
| JSML | Janus Henderson Small Cap Growth Alpha ETF | 0.84% |
| IHE | iShares U.S. Pharmaceuticals ETF | 0.83% |
Weight is the stock’s share of each fund’s holdings.
